Skip to main content
Mabion S.A. logo

Mabion S.A. — Investor Relations & Filings

Ticker · MAB ISIN · PLMBION00016 LEI · 259400KG5JVQPPZL6X53 WAR Manufacturing
Open in API
Filings indexed 1,002 across all filing types
Latest filing 2021-04-13 Report Publication Anno…
Country PL Poland
Listing WAR MAB

About Mabion S.A.

https://www.mabion.eu/en/

Mabion S.A. is an integrated Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services for the development and manufacturing of protein-based biotherapeutics. The company specializes in monoclonal antibodies and biosimilars, offering a complete workflow from cell line development and banking to process optimization and large-scale GMP manufacturing. Core competencies include upstream processing using mammalian cell cultures, downstream purification involving chromatography and viral clearance, and technology transfer for scale-up. Mabion partners with pharmaceutical and biotechnology companies to support both clinical and commercial supply, streamlining the path from gene to final drug product.

Recent filings

Filing Released Lang Actions
Zmiana terminu publikacji raportu rocznego za rok 2020 - Content (PL)
Report Publication Announcement Classification · 98% confidence The document text is very short (325 characters) and explicitly states that the company (Mabion S.A.) is informing the public about a *change in the date* for releasing its annual report for 2020. It announces *when* the report will be published (April 30, 2021), referencing a previous announcement. This is not the Annual Report (10-K) itself, but an announcement about the publication schedule of that report. According to Rule 2 (The 'Menu vs Meal' Rule), a short announcement regarding the timing or publication of a report points towards 'Report Publication Announcement' (RPA).
2021-04-13 Polish
Rejestracja podwyższenia kapitału zakładowego oraz zmiany Statutu Spółki - Content (EN)
Capital/Financing Update Classification · 98% confidence The document explicitly details the registration of an amendment to the Company's Articles of Association following a share capital increase (issue of series U shares) pursuant to an Extraordinary General Meeting resolution. It provides the new total share capital, the breakdown of all share series, and an amendment to the company's object of activity (PKD codes). This content relates directly to changes in the company's capital structure and foundational documents, which aligns best with the 'Capital/Financing Update' (CAP) category, as it reports the finalization of a capital increase. While it involves a resolution from a general meeting, the core subject is the resulting capital change, not the voting results (DVA) or the meeting presentation itself (AGM-R).
2021-04-02 English
Rejestracja podwyższenia kapitału zakładowego oraz zmiany Statutu Spółki - Content (PL)
Capital/Financing Update Classification · 98% confidence The document text is a formal announcement from the Management Board ("Zarząd") of Mabion S.A. detailing the registration of changes to the Company's Statute by the National Court Register (KRS). Specifically, it reports the increase in share capital following the issuance of Series U shares and the resulting new structure of the share capital, as well as changes to the company's business scope (§ 6 PKD codes). This type of filing, which reports a change in the capital structure (share issuance/increase) and subsequent statutory amendments, directly corresponds to the definition of a Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV).
2021-04-02 Polish
Informacje dotyczące realizacji pierwszego zamówienia w ramach umowy ramowej z Novavax, Inc. - Content (EN)
Capital/Financing Update Classification · 99% confidence The document is very short (807 characters) and appears to be a regulatory disclosure under MAR (Market Abuse Regulation) concerning an update on a framework agreement with Novavax, specifically mentioning the receipt of the first payment for a COVID-19 vaccine order. It is not a full financial report (like 10-K or IR), nor is it a standard announcement like a dividend or management change. It is a specific, material, non-standard update regarding a contract/financial event. Given the options, this type of specific, material, non-standard announcement that doesn't fit the other specific categories (like DIRS, DIV, MANG, etc.) is best categorized as a general Regulatory Filing (RNS), as it is a mandatory disclosure under market rules (MAR) that doesn't align with the more specific financial or corporate action codes provided.
2021-03-26 English
Informacje dotyczące realizacji pierwszego zamówienia w ramach umowy ramowej z Novavax, Inc. - Content (PL)
Regulatory Filings Classification · 99% confidence The document is very short (526 characters) and references a previous report (raport bieżący nr 15/2021) regarding a framework agreement with Novavax. The core message is an update that the company received the first payment and that the order execution is proceeding according to plan. This is a brief, specific operational update concerning a contract/order execution, which is not explicitly covered by the main financial reports (10-K, IR) or specific announcements like dividends or management changes. Given its nature as a brief, non-standard regulatory update concerning business operations/contracts, it fits best under the general 'Regulatory Filings' fallback category (RNS), as it is an announcement of an event rather than a comprehensive report.
2021-03-26 Polish
Rejestracja praw do akcji serii U Spółki w KDPW - Content (EN)
Regulatory Filings Classification · 95% confidence The document announces the registration of rights to series U shares in the National Depository for Securities (KDPW) and confirms the introduction of these rights to exchange trading on the Warsaw Stock Exchange. This action relates directly to the company's capital structure and the issuance/trading of securities (share rights). This fits best under 'Share Issue/Capital Change' (SHA), as it details a specific change related to the issuance of new shares/rights. It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend announcement (DIV). Since it is a specific announcement about a capital event, SHA is the most precise fit over the general fallback RNS.
2021-03-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.